Cannabinoids and the future of Novartis | Brazcann

Pharmaceutical

A vision of the future: cannabinoids and Novartis

Novartis could develop cannabinoid medicines for neurology and pain. Steer Novartis's research toward cannabinoid medicines in neurology and inflammation, areas with potential and growing clinical proof. Below, an independent strategic analysis by Brazcann on how this would be possible — and what the brand stands to gain.

If you're looking for «Novartis hemp», «Novartis and cannabis» or a cannabis medicine linked to Novartis, this report brings together the science, the potential of industrial cannabis and the business path behind the idea.

Novartis's current challenge

Novartis continually renews its pipeline and invests in innovative therapies. Cannabinoids offer a class with proof of concept, but require investment and regulatory navigation.

The science behind: cannabinoids as medicine

Cannabinoids are already active ingredients of medicines approved by agencies such as the FDA and the EMA. Pure cannabidiol (CBD) is the basis of Epidiolex, approved for severe, rare forms of epilepsy (Dravet and Lennox-Gastaut syndromes), with efficacy proven in randomized clinical trials published in the New England Journal of Medicine. Nabiximols (Sativex), a combination of THC and CBD, is registered for multiple sclerosis spasticity. There is ongoing clinical research in chronic pain, anxiety, chemotherapy nausea and sleep disorders.

CBD: active ingredient of a medicine approved for severe epilepsies (RCT evidence).
Nabiximols (THC:CBD): registered for multiple sclerosis spasticity.
Active clinical research in chronic pain, anxiety, oncology and sleep.
A globally expanding cannabinoid pharmaceutical market, with a growing pipeline.

How Novartis would apply cannabinoids as medicine

Novartis could develop cannabinoid candidates for pain and neurological conditions, leveraging its experience in clinical trials and high-standard registration.

A possible path

Prioritize neurological and inflammatory targets with cannabinoid evidence.
Develop pharmaceutical-quality molecules with its own intellectual property.
Advance through trials and international registration.

The potential gain (hypothetical scenario)

In a hypothetical scenario, Novartis would broaden its pipeline with a validated, expanding class — dependent on evidence and approval.

Sustainability: For pharma, the value lies less in the environmental footprint and more in expanding the therapeutic arsenal with a validated, still under-explored class of molecules.

The link with Brazil and Brazcann

In Brazil, cannabis health products are regulated by Anvisa — RDC 327/2019, RDC 660/2022 and the new framework RDC 1,015/2026 — which structure manufacturing, import, prescription and dispensing. This is exactly the regulatory ground where Brazcann operates.

Brazcann operates precisely at this bridge: regulatory intelligence, importing and structuring cannabis and hemp businesses in Brazil — helping companies turn scenarios like this into viable, Anvisa-compliant projects.

Frequently asked questions

Do cannabinoids have proven use?

Yes: cannabidiol is approved for severe forms of epilepsy, with efficacy in randomized trials.

Why invest in this?

It is a class with proof of concept and a growing market, lightly occupied by major players.

Is there a marijuana medicine?

The popular term is "marijuana", but the correct material here is industrial hemp — Cannabis sativa with THC ≤ 0.3%, with no psychoactive effect. It is the source of cannabinoids as medicine in this analysis. It is not a drug, but a renewable, sustainable industrial material.